PT986403E - Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua - Google Patents

Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua

Info

Publication number
PT986403E
PT986403E PT98928901T PT98928901T PT986403E PT 986403 E PT986403 E PT 986403E PT 98928901 T PT98928901 T PT 98928901T PT 98928901 T PT98928901 T PT 98928901T PT 986403 E PT986403 E PT 986403E
Authority
PT
Portugal
Prior art keywords
cyclodextrin
produkes
insolule
comprehening
decompose
Prior art date
Application number
PT98928901T
Other languages
English (en)
Portuguese (pt)
Inventor
Stella J Valentino
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Publication of PT986403E publication Critical patent/PT986403E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98928901T 1997-06-13 1998-06-12 Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua PT986403E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5090997P 1997-06-13 1997-06-13

Publications (1)

Publication Number Publication Date
PT986403E true PT986403E (pt) 2004-04-30

Family

ID=21968241

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98928901T PT986403E (pt) 1997-06-13 1998-06-12 Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua

Country Status (9)

Country Link
US (1) US6133248A (enExample)
EP (1) EP0986403B1 (enExample)
JP (1) JP4439596B2 (enExample)
AT (1) ATE253941T1 (enExample)
AU (1) AU750207B2 (enExample)
DE (1) DE69819721T2 (enExample)
ES (1) ES2210769T3 (enExample)
PT (1) PT986403E (enExample)
WO (1) WO1998056422A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
WO2003002152A2 (en) * 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US20030170216A1 (en) * 2001-12-20 2003-09-11 Schering-Plough Corporation SYN3 compositions and methods
WO2003072081A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
WO2003072141A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
SG185306A1 (en) 2004-04-15 2012-11-29 Onyx Therapeutics Inc Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) * 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
ES2408216T3 (es) * 2004-12-07 2013-06-19 Onyx Therapeutics, Inc. Composición para la inhibición del proteasoma
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
ES2415756T3 (es) 2005-11-09 2013-07-26 Onyx Therapeutics, Inc. Compuestos para la inhibición de enzimas
AU2006315169A1 (en) * 2005-11-15 2007-05-24 Baxter Healthcare S.A. Compositions comprising lipoxygenase inhibitors and cyclodextrin
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
ES2415632T3 (es) 2006-06-19 2013-07-26 Onyx Therapeutics, Inc. Epoxicetonas peptídicas para la inhibición del proteosoma
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
DK2061458T3 (en) * 2006-09-15 2015-03-09 Univ Minnesota Topiramate compositions and methods for their use
CA2685331C (en) 2007-04-27 2016-07-05 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
EP2207791B2 (en) 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
ES2378373T3 (es) * 2008-05-19 2012-04-11 Texcontor Etablissement Composición de fosfenitoína.
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
KR101912709B1 (ko) 2009-05-13 2018-10-30 사이덱스 파마슈티칼스, 인크. 프라수그렐 및 사이클로덱스트린 유도체를 포함하는 약학 조성물 및 그의 제조 및 사용 방법
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
EP2434886B1 (en) 2009-05-29 2019-10-16 CyDex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
HUE033442T2 (en) 2009-06-25 2017-11-28 Alkermes Pharma Ireland Ltd Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (en) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
JP5848761B2 (ja) 2010-06-24 2016-01-27 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ:エステル、カルボネート、カルバメートおよびホスホネートの誘導体
DE102011011028A1 (de) * 2011-02-11 2012-08-16 Ditter Plastic Gmbh + Co. Kg Frontplatte mit darin eingespritztem Lichtleiter
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
EP2758052B9 (en) 2011-09-18 2019-03-27 Euro-Celtique S.A. Pharmaceutical composition comprising an HDAC inhibitor and a cyclopolysaccharide
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
PT3702374T (pt) 2012-02-15 2022-06-23 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
CN110066351B (zh) 2012-02-28 2022-06-14 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
JP6557144B2 (ja) 2012-10-22 2019-08-07 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
FI3183295T3 (fi) 2014-08-22 2023-09-25 Cydex Pharmaceuticals Inc Fraktioidut alkyloidut syklodekstriinikoostumukset ja menetelmät niiden valmistamiseksi ja käyttämiseksi
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP2022522928A (ja) 2018-12-18 2022-04-21 ムンディファーマ・インターナショナル・コーポレーション・リミテッド 多発性骨髄腫を治療するための化合物
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN110279664B (zh) * 2019-07-30 2021-09-03 四川农业大学 一种氟苯尼考包合物冻干粉针剂及其制备方法
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル,インク. 医薬化合物の錯化剤塩製剤
CN118161457A (zh) * 2020-12-04 2024-06-11 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
AU2020480182B2 (en) 2020-12-04 2025-02-27 Sichuan Credit Pharmaceutical Co., Ltd Fosphenytoin sodium solid composition, lyophilization method, and use of fosphenytoin sodium solid composition
EP4525916A1 (en) * 2022-05-18 2025-03-26 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
WO2024231293A1 (en) 2023-05-05 2024-11-14 Euro-Celtique S.A. Combinations for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
US4616008A (en) * 1984-05-02 1986-10-07 Takeda Chemical Industries, Ltd. Antibacterial solid composition for oral administration
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4925860A (en) * 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
DE3938227C1 (en) * 1989-11-17 1991-05-02 Dolorgiet Gmbh & Co Kg, 5205 St Augustin, De Oral antiinflammatory and analgetic pharmaceutical compsn. - comprises magnesium ibuprofen dissolved in mixt. of water, propane-1,2-diol and glycerol
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ES2118673T3 (es) * 1996-10-29 2001-04-16 Staroil Ltd Composiciones solubles en la boca que contienen n-acetilcisteina y ciclodextrina.

Also Published As

Publication number Publication date
AU750207B2 (en) 2002-07-11
EP0986403A1 (en) 2000-03-22
US6133248A (en) 2000-10-17
ES2210769T3 (es) 2004-07-01
EP0986403B1 (en) 2003-11-12
JP4439596B2 (ja) 2010-03-24
DE69819721T2 (de) 2004-09-23
DE69819721D1 (de) 2003-12-18
JP2002511861A (ja) 2002-04-16
WO1998056422A1 (en) 1998-12-17
ATE253941T1 (de) 2003-11-15
AU8059198A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
PT986403E (pt) Composicao com um tempo de vida de armazenagem prolongado compreendendo a ciclodextrina e drogas ou prodrogas que se decompoem em compostos insoluveis em agua
IT1196033B (it) Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
BR0014869A (pt) Composição e método para estabilização da mesma
FI971486A0 (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
YU47204B (sh) Derivati didehidro-vitamina d3
DZ2744A1 (fr) Distribution d'un agent actif aérosolé.
FR2451192A1 (fr) Agent de prevention de la mauvaise haleine contenant de la cyclodextrine
MA26548A1 (fr) Compositions pharmaceutiques topiques contenant des derives de resorcinol.
BR0010194A (pt) Composição farmacêutica sob a forma unitária, contendo o ácido acetilsalicìlico e hidrogenossulfato de clopidogrel
BR9810495A (pt) Composição farmacêutica
BR9805326A (pt) Composição com liberação controlada, e, processos para controlar a liberação de compostos biologicamente ativos e controlar ou inibir o crescimento de pragas em um local.
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
NO985232L (no) Androstenderivater
BR0006005A (pt) Composição estável de óleo em glicerinatopicamente aplicável
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
AR011846A1 (es) Una composicion farmaceutica, y el procedimiento para prepararla
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
MY130441A (en) Solutions containing epinastin
BR9809057A (pt) Composições antitussìgenas
BR9811458A (pt) "sistema solvente para penetração melhorada de compostos farmacêuticos"
BR9805875A (pt) Composições farmacêuticas de droloxifeno.
ES2194279T3 (es) Composiciones de ciclodextrina que contienen un derivado de avermectina o de milbemicina.
ES2169223T3 (es) Substancia anticancerosa que inhibe la metastasis cancerosa.